BR112022026747A2 - Métodos de tratamento do distúrbio do espectro da neuromielite óptica - Google Patents

Métodos de tratamento do distúrbio do espectro da neuromielite óptica

Info

Publication number
BR112022026747A2
BR112022026747A2 BR112022026747A BR112022026747A BR112022026747A2 BR 112022026747 A2 BR112022026747 A2 BR 112022026747A2 BR 112022026747 A BR112022026747 A BR 112022026747A BR 112022026747 A BR112022026747 A BR 112022026747A BR 112022026747 A2 BR112022026747 A2 BR 112022026747A2
Authority
BR
Brazil
Prior art keywords
methods
treatment
nmosd
spectrum disorders
neuromyelitis
Prior art date
Application number
BR112022026747A
Other languages
English (en)
Portuguese (pt)
Inventor
Rees William
Katz Eliezer
Smith Michael
Mittereder Nanette
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of BR112022026747A2 publication Critical patent/BR112022026747A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112022026747A 2020-06-30 2021-06-30 Métodos de tratamento do distúrbio do espectro da neuromielite óptica BR112022026747A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063046133P 2020-06-30 2020-06-30
US202063052093P 2020-07-15 2020-07-15
US202063071092P 2020-08-27 2020-08-27
PCT/US2021/039911 WO2022006283A2 (en) 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder

Publications (1)

Publication Number Publication Date
BR112022026747A2 true BR112022026747A2 (pt) 2023-01-24

Family

ID=79321915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026747A BR112022026747A2 (pt) 2020-06-30 2021-06-30 Métodos de tratamento do distúrbio do espectro da neuromielite óptica

Country Status (11)

Country Link
US (1) US20230406928A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172211A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023534916A (cg-RX-API-DMAC7.html)
KR (1) KR20230030642A (cg-RX-API-DMAC7.html)
CN (1) CN116234571A (cg-RX-API-DMAC7.html)
AU (1) AU2021299307A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026747A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178954A1 (cg-RX-API-DMAC7.html)
IL (1) IL299381A (cg-RX-API-DMAC7.html)
MX (1) MX2022016236A (cg-RX-API-DMAC7.html)
WO (1) WO2022006283A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7900888B2 (ja) * 2020-10-29 2026-08-05 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗cd19抗体の使用
CN117797245A (zh) * 2023-12-29 2024-04-02 广州赛莱拉干细胞科技股份有限公司 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101977843B1 (ko) * 2017-02-16 2019-05-13 국립암센터 시신경척수염 및 다발성경화증의 선별을 위한 바이오마커 및 이의 이용
CN110522908A (zh) * 2018-05-25 2019-12-03 荣昌生物制药(烟台)有限公司 TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
EP3959241A4 (en) * 2019-04-24 2023-01-25 Viela Bio, Inc. USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE
JP7900888B2 (ja) * 2020-10-29 2026-08-05 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗cd19抗体の使用

Also Published As

Publication number Publication date
WO2022006283A2 (en) 2022-01-06
MX2022016236A (es) 2023-03-29
CA3178954A1 (en) 2022-01-06
KR20230030642A (ko) 2023-03-06
EP4172211A4 (en) 2024-07-10
EP4172211A2 (en) 2023-05-03
US20230406928A1 (en) 2023-12-21
WO2022006283A3 (en) 2022-02-03
AU2021299307A1 (en) 2022-12-22
IL299381A (en) 2023-02-01
CN116234571A (zh) 2023-06-06
JP2023534916A (ja) 2023-08-15

Similar Documents

Publication Publication Date Title
BRPI0922650A2 (pt) Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina
BRPI0515884A (pt) métodos de diagnóstico e tratamento de complicações da gravidez
AR080564A1 (es) Metodos para el tratamiento o prevencion de enfermedades asociadas al receptor del factor de crecimiento epidermico humano-3 (her-3)
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
BRPI0910993A2 (pt) técnica de administração na linha de sutura usando toxinas botulínicas
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
BR112023019427A2 (pt) Sistema e método para determinar um cronograma de tratamento
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
BRPI0417493B8 (pt) uso de uma toxina botulínica para tratamento de distúrbios da pele
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
BR112022026999A2 (pt) Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
BR112021024634A2 (pt) Método de tratamento ou prevenção de um distúrbio, doença ou condição aliviada pela estimulação ou modulação da expressão de colágeno
Koike et al. Application of functional near infrared spectroscopy as supplementary examination for diagnosis of clinical stages of psychosis spectrum
BR112021021141A2 (pt) Método para modular estrutura glicocalyx endotelial
JOP20230125A1 (ar) كانابيديول لعلاج النوبات المستعصية على العلاج
BR112022023928A2 (pt) Uso de canabidiol para o tratamento do transtorno do espectro autista
BR112022008886A2 (pt) Diagnóstico de transtornos de humor usando biomarcadores de edição de rna do sangue
BR112021019854A2 (pt) Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares
Zhang et al. Knockdown of OLA1, a regulator of oxidative stress response, inhibits motility and invasion of breast cancer cells
Kalotra et al. 5‐Nonyloxytryptamine oxalate–embedded collagen–laminin scaffolds augment functional recovery after spinal cord injury in mice
Simhadri et al. Dysregulation of LIMK‐1/cofilin‐1 pathway: a possible basis for alteration of neuronal morphology in experimental cerebral malaria
BR112023023558A2 (pt) Anticorpos anti-tmprss6 e usos dos mesmos
Suto et al. Rat model of attention-deficit hyperactivity disorder exhibits delayed recovery from acute incisional pain due to impaired descending noradrenergic inhibition
MX2022016236A (es) Metodos de tratamiento del trastorno del espectro de la neuromielitis optica.
Isik et al. SIRT1, MMP-9 and TIMP-1 levels in children with specific learning disorder

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: VIELA BIO, INC. (US)